BACKGROUND: Several serum biomarkers have been studied to diagnose incidence and severity of traumatic brain injury (TBI), but a reliable biomarker in TBI has yet to be identified. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) has been proposed as a biomarker in clinical and preclinical studies, largely in the setting of isolated TBI or concussion. The aim of this study was to evaluate the performance of UCH-L1 as a serum biomarker in the setting of polytrauma and TBI. METHODS: Multiple variations of murine TBI and polytrauma models were used to evaluate serum biomarkers. The different models included TBI with and without hemorrhagic shock and resuscitation, isolated extremity vascular ligation, extremity ischemia/reperfusion, and blunt tail injury. Blood was drawn at intervals after injury, and serum levels of neuron-specific enolase, UCH-L1, creatine kinase, and syndecan-1 were evaluated by enzyme-linked immunosorbent assay. RESULTS: UCH-L1 levels were not significantly different between TBI, tail injury, and sham TBI. By contrast, neuron-specific enolase levels were increased in TBI mice compared with tail injury and sham TBI mice. UCH-L1 levels increased regardless of TBI status at 30 min and 4 h after hemorrhagic shock and resuscitation. In mice that underwent femoral artery cannulation followed by hemorrhagic shock/resuscitation, UCH-L1 levels were significantly elevated compared with shock sham mice at 4 h (3158 ± 2168 pg/mL, 4 h shock versus 0 ± 0 pg/mL, 4 h shock sham; P < 0.01) and at 24 h (3253 ± 2954 pg/mL, 24 h shock versus 324 ± 482 pg/mL, 24 h shock sham; P = 0.03). No differences were observed in UCH-L1 levels between the sham shock and the arterial ligation, vein ligation, or extremity ischemia/reperfusion groups at any time point. Similar to UCH-L1, creatine kinase was elevated only after shock compared with sham mice at 4, 24, and 72 h after injury. CONCLUSIONS: Our study demonstrates that UCH-L1 is not a specific marker for TBI but is elevated in models that induce central and peripheral nerve ischemia. Given the increase in UCH-L1 levels observed after hemorrhagic shock, we propose that UCH-L1 may be a useful adjunct in quantifying severity of shock or global ischemia rather than as a specific marker of TBI.
BACKGROUND: Several serum biomarkers have been studied to diagnose incidence and severity of traumatic brain injury (TBI), but a reliable biomarker in TBI has yet to be identified. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) has been proposed as a biomarker in clinical and preclinical studies, largely in the setting of isolated TBI or concussion. The aim of this study was to evaluate the performance of UCH-L1 as a serum biomarker in the setting of polytrauma and TBI. METHODS: Multiple variations of murineTBI and polytrauma models were used to evaluate serum biomarkers. The different models included TBI with and without hemorrhagic shock and resuscitation, isolated extremity vascular ligation, extremity ischemia/reperfusion, and blunt tail injury. Blood was drawn at intervals after injury, and serum levels of neuron-specific enolase, UCH-L1, creatine kinase, and syndecan-1 were evaluated by enzyme-linked immunosorbent assay. RESULTS:UCH-L1 levels were not significantly different between TBI, tail injury, and sham TBI. By contrast, neuron-specific enolase levels were increased in TBImice compared with tail injury and sham TBImice. UCH-L1 levels increased regardless of TBI status at 30 min and 4 h after hemorrhagic shock and resuscitation. In mice that underwent femoral artery cannulation followed by hemorrhagic shock/resuscitation, UCH-L1 levels were significantly elevated compared with shock sham mice at 4 h (3158 ± 2168 pg/mL, 4 h shock versus 0 ± 0 pg/mL, 4 h shock sham; P < 0.01) and at 24 h (3253 ± 2954 pg/mL, 24 h shock versus 324 ± 482 pg/mL, 24 h shock sham; P = 0.03). No differences were observed in UCH-L1 levels between the sham shock and the arterial ligation, vein ligation, or extremity ischemia/reperfusion groups at any time point. Similar to UCH-L1, creatine kinase was elevated only after shock compared with sham mice at 4, 24, and 72 h after injury. CONCLUSIONS: Our study demonstrates that UCH-L1 is not a specific marker for TBI but is elevated in models that induce central and peripheral nerve ischemia. Given the increase in UCH-L1 levels observed after hemorrhagic shock, we propose that UCH-L1 may be a useful adjunct in quantifying severity of shock or global ischemia rather than as a specific marker of TBI.
Authors: P E Vos; B Jacobs; T M J C Andriessen; K J B Lamers; G F Borm; T Beems; M Edwards; C F Rosmalen; J L M Vissers Journal: Neurology Date: 2010-11-16 Impact factor: 9.910
Authors: Michael D Goodman; Amy T Makley; Nathan L Huber; Callisia N Clarke; Lou Ann W Friend; Rebecca M Schuster; Stephanie R Bailey; Stephen L Barnes; Warren C Dorlac; Jay A Johannigman; Alex B Lentsch; Timothy A Pritts Journal: J Surg Res Date: 2010-06-16 Impact factor: 2.192
Authors: Xian-Jian Huang; Olena Glushakova; Stefania Mondello; Ken Van; Ronald L Hayes; Bruce G Lyeth Journal: J Neurotrauma Date: 2015-05-14 Impact factor: 5.269
Authors: Michael A Flierl; Philip F Stahel; Kathryn M Beauchamp; Steven J Morgan; Wade R Smith; Esther Shohami Journal: Nat Protoc Date: 2009-08-27 Impact factor: 13.491
Authors: Ramon Diaz-Arrastia; Kevin K W Wang; Linda Papa; Marco D Sorani; John K Yue; Ava M Puccio; Paul J McMahon; Tomoo Inoue; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; David O Okonkwo; Geoffrey T Manley Journal: J Neurotrauma Date: 2013-10-09 Impact factor: 5.269
Authors: Mathias Gelderblom; Tristan Daehn; Benjamin Schattling; Peter Ludewig; Christian Bernreuther; Priyadharshini Arunachalam; Jakob Matschke; Markus Glatzel; Christian Gerloff; Manuel A Friese; Tim Magnus Journal: Neurobiol Dis Date: 2013-08-09 Impact factor: 5.996
Authors: Linda Papa; Gretchen M Brophy; Robert D Welch; Lawrence M Lewis; Carolina F Braga; Ciara N Tan; Neema J Ameli; Marco A Lopez; Crystal A Haeussler; Diego I Mendez Giordano; Salvatore Silvestri; Philip Giordano; Kurt D Weber; Crystal Hill-Pryor; Dallas C Hack Journal: JAMA Neurol Date: 2016-05-01 Impact factor: 18.302
Authors: Taylor E Wallen; Kathleen E Singer; Matthew R Baucom; Lisa G England; Rebecca M Schuster; Timothy A Pritts; Michael D Goodman Journal: J Trauma Acute Care Surg Date: 2022-03-22 Impact factor: 3.697
Authors: Mackenzie C Morris; Devin John; Kathleen E Singer; Ryan Moran; Emily McGlone; Rosalie Veile; Holly S Goetzman; Amy T Makley; Charles C Caldwell; Michael D Goodman Journal: Thromb Res Date: 2020-08-07 Impact factor: 3.944